ARS Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
8.48 |
79.79 |
206.46 |
361.37 |
527.03 |
729.93 |
| Przychód Δ r/r |
0.00% |
840.96% |
158.75% |
75.03% |
45.84% |
38.50% |
| Przychód (min) |
2.26 |
51.84 |
117.86 |
356.08 |
326.54 |
452.25 |
| Przychód (max) |
14.70 |
121.46 |
248.97 |
366.66 |
684.36 |
947.82 |
| EBITDA (średnia) |
-5.19 |
-48.81 |
-126.28 |
-221.03 |
-322.35 |
-446.46 |
| EBIT (średnia) |
-5.35 |
-50.37 |
-130.34 |
-228.13 |
-332.71 |
-460.79 |
| EBIT % |
-63.13% |
-63.13% |
-63.13% |
-63.13% |
-63.13% |
-63.13% |
| Zysk netto (średni) |
-53.43 |
-146.81 |
-66.40 |
31.34 |
127.88 |
233.04 |
| Zysk netto % |
-630.12% |
-183.98% |
-32.16% |
8.67% |
24.26% |
31.93% |
| EPS (średnia) |
-0.66 |
-1.43 |
-0.64 |
0.32 |
1.25 |
2.28 |
| Liczba analityków (Przychody) |
4 |
4 |
6 |
5 |
1 |
2 |
| Liczba analityków (EPS) |
4 |
4 |
5 |
5 |
2 |
1 |
| symbol |
SPRY |
SPRY |
SPRY |
SPRY |
SPRY |
SPRY |